Related references
Note: Only part of the references are listed.Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma
Ayesha Noorani et al.
NATURE GENETICS (2020)
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
Nitin Roper et al.
CELL REPORTS MEDICINE (2020)
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer
Gillianne Gy Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
Seulki Kim et al.
CANCER RESEARCH AND TREATMENT (2019)
An analysis of genetic heterogeneity in untreated cancers
Johannes G. Reiter et al.
NATURE REVIEWS CANCER (2019)
Cancer biology as revealed by the research autopsy
Christine A. Iacobuzio-Donahue et al.
NATURE REVIEWS CANCER (2019)
An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer
Clara Mayo-de-Las-Casas et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2018)
Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective
Mathilde Postel et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2018)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Lung Cancer Heterogeneity and New Strategies for Drug Therapy
Diane C. Wang et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58 (2018)
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Samra Turajlic et al.
CELL (2018)
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer
Ryo Ariyasu et al.
LUNG CANCER (2018)
FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
Yi Xiao et al.
MOLECULAR ONCOLOGY (2018)
Heterogeneity in Lung Cancer
Vitor Manuel Leitao de Sousa et al.
PATHOBIOLOGY (2018)
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
David Tamborero et al.
GENOME MEDICINE (2018)
Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0)
Kuniko Sunami et al.
CANCER SCIENCE (2018)
FBXW7: a critical tumor suppressor of human cancers
Chien-Hung Yeh et al.
MOLECULAR CANCER (2018)
Minimal functional driver gene heterogeneity among untreated metastases
Johannes G. Reiter et al.
SCIENCE (2018)
Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance
Youngtae Jeong et al.
CANCER DISCOVERY (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma
Claire L. Meaney et al.
ONCOTARGET (2017)
Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer
Kenichi Suda et al.
LUNG CANCER (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
Drug resistance in cancer: molecular evolution and compensatory proliferation
Ran Friedman
ONCOTARGET (2016)
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska et al.
CANCER DISCOVERY (2015)
Lung Cancer Screening: The European Perspective
Giulia Veronesi
THORACIC SURGERY CLINICS (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
Effectiveness of Gefitinib against Non-Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
Satoshi Watanabe et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
FBXW7 Mediates Chemotherapeutic Sensitivity and Prognosis in NSCLCs
Takehiko Yokobori et al.
MOLECULAR CANCER RESEARCH (2014)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer
Jenn-Yu Wu et al.
CLINICAL CANCER RESEARCH (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Gain of Nrf2 Function in Non-Small-Cell Lung Cancer Cells Confers Radioresistance
Anju Singh et al.
ANTIOXIDANTS & REDOX SIGNALING (2010)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Global Downstream Pathway Analysis Reveals a Dependence of Oncogenic NF-E2-Related Factor 2 Mutation on the mTOR Growth Signaling Pathway
Tatsuhiro Shibata et al.
CANCER RESEARCH (2010)
Ionizing Radiation Activates the Nrf2 Antioxidant Response
J. Tyson McDonald et al.
CANCER RESEARCH (2010)
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
Michio Inukai et al.
CANCER RESEARCH (2006)
Share Paper
